Sanofi (SAN.PA) Stock Analysis
Free AI-powered analysis and research for Sanofi stock
Sector: Healthcare
SAN.PA snapshot
Data as of 11 Nov 2026 close. Updated daily.
Sanofi scores 79/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 80% of its 52-week range, down 3.9% over the past year. Latest reported figures show a profit margin of 8.2%, return on equity of 5.7% and revenue growth of +15.7%.
What is driving the score
- RSI Very High (81): -5
- Strong Uptrend: +12
- MACD Bullish: +8
- Strong Revenue Growth (15.7%): +8
- Low Debt (0.27 D/E): +8
- Weak Liquidity (1.12 Current Ratio): -5
- Strong Long-term Uptrend: +8
- Underperforming (-3.9% over 1 year): -5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full SAN.PA report
Sanofi (SAN.PA) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze SAN.PA Now βπ° Latest Update
Sanofi (SNY) Is Planning for a Patent Loss, Hereβs Where Bulls Still See Opportunity
Tue, November 10, 2026 at 10:22 PM UTC 2 min read
Sanofi (SNY) was recently upgraded by BNP Paribas to Outperform, highlighting its growth potential driven by Dupixent, which saw a 34.8% increase in sales to β¬5.7 billion. Despite concerns over future patent losses and declining vaccine sales, analysts see opportunities in Sanofi's expanding product base and rising profits through 2030. The company is prioritizing planning for Dupixent's patent expiration while continuing to develop next-generation therapies in collaboration with Regeneron.